Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma
2008
Аутори
Juranić, ZoricaRadić, Jelena
Konić-Ristić, Aleksandra
Jelić, Svetislav
Mihaljević, Biljana
Stanković, Ivan
Matković, Suzana
Besu, Irina
Gavrilović, Dušica
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Background: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen. Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test. Results: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher se...rum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls (P lt 0.02) Conclusion: Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease.
Извор:
BMC Immunology, 2008, 9Издавач:
- BMC, LONDON
Финансирање / пројекти:
- Истраживање дејстава модификатора биолошког одговора у физиолошким и патолошким стањима (RS-MESTD-MPN2006-2010-145006)
- Тумори горњих аеродигестивних путева и околних и сродних структура: биолошко понашање субпопулација; маркери предикције, прогнозе, осетљивости и прогресије; могућности модулације различитих терапијских модалитета на молекуларном нивоу (RS-MESTD-MPN2006-2010-145055)
DOI: 10.1186/1471-2172-9-22
ISSN: 1471-2237
PubMed: 18507842
WoS: 000256602100001
Scopus: 2-s2.0-44949172461
Институција/група
PharmacyTY - JOUR AU - Juranić, Zorica AU - Radić, Jelena AU - Konić-Ristić, Aleksandra AU - Jelić, Svetislav AU - Mihaljević, Biljana AU - Stanković, Ivan AU - Matković, Suzana AU - Besu, Irina AU - Gavrilović, Dušica PY - 2008 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1071 AB - Background: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen. Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test. Results: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls (P lt 0.02) Conclusion: Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease. PB - BMC, LONDON T2 - BMC Immunology T1 - Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma VL - 9 DO - 10.1186/1471-2172-9-22 ER -
@article{ author = "Juranić, Zorica and Radić, Jelena and Konić-Ristić, Aleksandra and Jelić, Svetislav and Mihaljević, Biljana and Stanković, Ivan and Matković, Suzana and Besu, Irina and Gavrilović, Dušica", year = "2008", abstract = "Background: Multiple myeloma (MM) is a clonal B-cell disorder with many immunological disturbances. The aim of this work was to assess whether some of food antigens contribute to the imbalance of immune response by screening the sera of MM patients for their immunoreactivity to food constituent gliadin, to tissue transglutaminase-2 (tTG-2) and to Ro/SSA antigen. Sera from 61 patients with MM in various stages of disease, before, or after some cycles of conventional therapy were analyzed by commercial Binding Site ELISA tests. The control group consisted of 50 healthy volunteers. Statistical analysis of data obtained was performed by Mann Whitney Test. Results: The higher serum IgA immunoreactivity to gliadin was found in 14/56 patients and in one of control people. The enhanced serum IgG immunoreactivity to gliadin was found in only two of tested patients and in two controls. The enhanced IgA immunoreactivity to tTG-2 was found in 10/49 patients' sera, while 4/45 patients had higher serum IgG immunoreactivity. The enhanced serum IgG immunoreactivity to RoSSA antigen was found in 9/47 analyzed MM patients' sera. Statistical analysis of data obtained revealed that only the levels of anti-tTG-2 IgA immunoreactivity in patients with MM were significantly higher than these obtained in healthy controls (P lt 0.02) Conclusion: Data obtained showed the existence of the enhanced serum immunoreactivity to gliadin, tTG-2 and Ro/SSA antigens in some patients with MM. These at least partially could contribute to the immunological imbalance frequently found in this disease.", publisher = "BMC, LONDON", journal = "BMC Immunology", title = "Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma", volume = "9", doi = "10.1186/1471-2172-9-22" }
Juranić, Z., Radić, J., Konić-Ristić, A., Jelić, S., Mihaljević, B., Stanković, I., Matković, S., Besu, I.,& Gavrilović, D.. (2008). Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma. in BMC Immunology BMC, LONDON., 9. https://doi.org/10.1186/1471-2172-9-22
Juranić Z, Radić J, Konić-Ristić A, Jelić S, Mihaljević B, Stanković I, Matković S, Besu I, Gavrilović D. Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma. in BMC Immunology. 2008;9. doi:10.1186/1471-2172-9-22 .
Juranić, Zorica, Radić, Jelena, Konić-Ristić, Aleksandra, Jelić, Svetislav, Mihaljević, Biljana, Stanković, Ivan, Matković, Suzana, Besu, Irina, Gavrilović, Dušica, "Humoral immunoreactivity to gliadin and to tissue transglutaminase is present in some patients with multiple myeloma" in BMC Immunology, 9 (2008), https://doi.org/10.1186/1471-2172-9-22 . .